Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 9:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 13,929 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Trial Clear all

Conditions: Pelvic Organ Prolapse, Cystocele, Uterine Prolapse
Interventions: Absorbent suture (polydioxanone) and Permanent suture (Gore-Tex CV2); Device
Lead sponsor: Joseph Kowalski; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Immune
Interventions: Amunizer, Placebo; Dietary Supplement · Other
Lead sponsor: Nutraceuticals Research Institute; Other
Eligibility: 20 Years to 65 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Franklin, Tennessee

Conditions: Hypertension, Multiple Chronic Conditions
Interventions: Enhanced COACH CDS Tool, Usual Care COACH CDS Tool; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Columbia, Missouri • Portland, Oregon • Nashville, Tennessee

Conditions: Surgical Complication, Paresthesia, Fracture, Nerve Injury, Nerve Entrapments, Mandibular Nerve Injuries, Mandibular Hypoplasia, Mandibular Retrognathism, Mandibular Hyperplasia, Mandibular Prognathism
Interventions: Sonopet ultrasonic saw, Reciprocating saw; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: Up to 45 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Tissue and Organ Procurement, Health Behavior
Interventions: video; Behavioral
Lead sponsor: Case Western Reserve University; Other
Eligibility: 15 Years and older
Enrollment: 973 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Breast Cancer, Breast Cancer Female, Muscle Weakness
Interventions: Creatine; Dietary Supplement
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Craniofacial Pain, Migraine, Cluster Headache, Trigeminal Autonomic Cephalgia, Sphenopalatine Ganglion Neuralgia, Paroxysmal Hemicrania
Interventions: Exparel (Bupivacaine Liposome), Saline; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Stanford, California

Conditions: Healthy
Interventions: VIS954, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Inflammation
Interventions: Omega 7 + 3, Omega 3, Placebo; Dietary Supplement
Lead sponsor: Appalachian State University; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Kannapolis, North Carolina

Conditions: Clostridium Difficile Colitis
Interventions: CRS3123, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diarrhea, Gastroenteritis
Interventions: Zinc Sulfate, Placebo oral capsule; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 6 Months to 6 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: PTSD
Interventions: Quetiapine, Placebo; Drug
Lead sponsor: Ralph H. Johnson VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 2
States / cities: Albuquerque, New Mexico • Charleston, South Carolina

Conditions: Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure
Interventions: Cordella™ Pulmonary Artery Sensor System; Device
Lead sponsor: Endotronix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 45
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 35 more

Conditions: Urinary Tract Infections, Urinary Retention Postoperative, Pelvic Organ Prolapse
Interventions: Methenamine Hippurate 1 g tablet, Placebo tablet; Drug
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Pathological Gambling
Interventions: Bupropion, Placebo; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Depressive Disorder, Major
Interventions: 5 mg BI 1569912, Placebo matching BI 1569912, 10 mg BI 1569912, 20 mg of BI 1569912; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 35
States / cities: Bellflower, California • Long Beach, California • Oceanside, California + 31 more

Conditions: End Stage Renal Failure on Dialysis
Interventions: Amino acid supplementation NephrAmine®; Dietary Supplement
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Urge Incontinence
Interventions: Interstim (SNS); Device
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Orange, California

Conditions: Major Depression
Interventions: Psilocybin; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 5
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Portland, Oregon + 2 more

Conditions: Gout
Interventions: pegloticase; Biological
Lead sponsor: Savient Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 22
States / cities: San Francisco, California • Santa Maria, California • Whittier, California + 19 more

Conditions: HIV Infections, Hepatitis C
Interventions: Ribavirin, Interferon alfa-2a, Peginterferon alfa-2a; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 24
States / cities: San Diego, California • San Francisco, California • Aurora, Colorado + 12 more

Conditions: Knee Arthroplasty, Total, Osteoarthritis, Radiologic Tibiofemoral Osteoarthritis
Interventions: Genicular Nerve RFA, Sham Genicular Nerve RFA; Procedure
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 45 Years to 79 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Diabetes Mellitus, Type II
Interventions: Placebo, PF-06291874; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 19
States / cities: Anaheim, California • Chula Vista, California • Walnut Creek, California + 13 more

Conditions: Rheumatoid Arthritis
Interventions: Humax-CD4, Placebo; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 50
States / cities: Montgomery, Alabama • Long Beach, California • Rancho Cucamonga, California + 45 more

Search by objective public record fields.

A Randomized Controlled Trial of Permanent vs Absorbable Suture for Uterosacral Ligament Suspension

Beverage for Immune Support

Collaboration Oriented Approach to Controlling High Blood Pressure

Trial of Bilateral Sagittal Split Osteotomy Induced Paresthesia Using Ultrasonic vs. Reciprocating Saw Instrumentation

Community Trial to Enhance Organ Donation

THRIVE Well Cancer FDTN/Exercise_Creatine Supplementation

Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain

A Study to Evaluate Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Multiple Doses of VIS954

Omega 7 + 3 Combination and Systemic Inflammation

Phase I Trial of a Single Dose of CRS3123

Oral Zinc for the Treatment of Acute Diarrhea in US Children

Quetiapine Treatment for Post-Traumatic Stress Disorder (PTSD)

PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III

Urinary Track Infection Prevention After Urogynecological Surgery

Bupropion in the Treatment of Pathological Gambling

A Study to Test Different Doses of BI 1569912 in People With Depression

Trial of Carbamylation in Renal Disease-Modulation With Amino Acid Therapy

Trial of Continuous Versus Cyclic Stimulation in Interstim Therapy

Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression

Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout

A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)

Genicular Radiofrequency Ablation Efficacy in Achieving Total Knee Pain Reduction Trial

Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus

Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker